xanomeline + trospium chloride

**Xanomeline + trospium chloride** is an oral fixed-dose small-molecule combination marketed in the United States as **Cobenfy** and previously developed as **KarXT**. It combines xanomeline, a dual muscarinic acetylcholine receptor M1 and M4-preferring agonist intended to provide central antipsychotic activity without dopamine D2 receptor blockade, with trospium chloride, a peripherally restricted pan-muscarinic antagonist that reduces xanomeline-associated peripheral cholinergic adverse effects. The FDA approved Cobenfy in 2024 for treatment of schizophrenia in adults. Bristol Myers Squibb acquired Karuna Therapeutics, the principal developer of KarXT, in March 2024. ([accessdata.fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216158s000lbl.pdf))

Brand names

Cobenfy

Other names

XTxanomeline + trospium chloridexanomeline and trospium chloridexanomeline-trospiumxanomeline-trospium chloridexanomeline/trospiumxanomeline/trospium chloride